Beamion BCGC-1Recruiting

A study of the new drug zongertinib, both as a single agent and in combination with other therapies, in various advanced HER2-positive cancers

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
Relapsed / refractory
Phase
Phase I/II

What is this trial about?

New targeted therapies are being investigated for various advanced cancers in which the HER2 receptor is overexpressed on tumor cells, with the aim of expanding treatment options. The goal of the Beamion BCGC-1 study is to determine an appropriate dosage for the new drug and to investigate whether it can shrink tumors on its own or in combination with other medications. Women and men aged 18 and older with metastatic (spread to other parts of the body) -positive breast cancer, stomach or (), or , and for whom previous treatment was no longer effective, are eligible to participate in this study.

Trial flow

Requirements

Diagnosis: Breast Cancer (mBC), Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Colorectal Cancer (mCRC)

Age: 18 years and older

Line of therapy: Rezidiv / primär refraktär

Key inclusion criteria: HER2-positive (HER2-overexpressing and/or amplified ); metastatic

Allocation

Randomisierung

Treatment

Follow-up

50 months

Detailed description

Breast cancer (mammary carcinoma), stomach cancer (gastric carcinoma), esophageal cancer (esophageal carcinoma), and colorectal cancer (colorectal carcinoma) are malignant diseases in which, in advanced or metastatic stages, the tumor can spread to other parts of the body. In some of these tumors, there is overexpression or alteration of the HER2 receptor on the cell surface, which promotes the growth of cancer cells. Depending on the type of cancer, there are already approved medications available for HER2-positive tumors, such as or the (T-DXd) and trastuzumab emtansine (T-DM1), which are administered as infusions. However, if the disease progresses despite these therapies, new treatment options are needed. Zongertinib is a selective HER2 taken orally as a tablet that binds to the HER2 receptor and is designed to specifically block the growth signal of cancer cells. The drug has not yet been approved for the treatment of the conditions being studied in this trial. The goal of this Phase 1b/2 study is to determine an appropriate dosage for the new active ingredient zongertinib and to investigate whether it can shrink tumors on its own or in combination with other medications. The study is open-label (not ), meaning that study physicians and patients know which drug is being administered. In Phase 1b (), the study will determine which dose of zongertinib, in combination with various other drugs, is well tolerated. In Phase 2 (dose optimization), patients will be randomly assigned to different groups to compare various dosages. There are several in which zongertinib is being evaluated either alone or in combination with trastuzumab deruxtecan, trastuzumab emtansine, trastuzumab (alone or in combination with , taken as a tablet), , or the chemotherapy regimen (administered as an infusion, with or without trastuzumab). Patients aged 18 and older with metastatic, HER2-positive breast cancer, stomach or esophageal cancer (adenocarcinoma), or colorectal cancer are eligible to participate in this study. Eligibility criteria include, among other things, that the disease has progressed following prior treatment (for breast, stomach, and esophageal cancer, following treatment targeting HER2) and that patients are in sufficiently good general health.

Facts

  1. Which disease: breast cancer, stomach cancer, ,
  2. Cancer characteristics: -positive (overexpressed and/or amplified), (for stomach and esophageal cancer), metastatic, advanced following prior treatment
  3. What the study investigates: alone and in combination with various other drugs (, emtansine, trastuzumab, , , )
  4. Study objective: To determine an appropriate dosage of zongertinib and to assess whether the drug, either alone or in combination, can shrink tumors
  5. Study duration: Treatment in ; the entire study is expected to run until January 2029 (approximately 4 years)
  6. Study characteristics: Phase 1b/2 study, open-label (unblinded), partially , sequential design, multiple treatment groups

Trial sites

6 trial sites in Germany are listed.

  • Universitätsklinikum Carl Gustav Carus Dresden

    Fetscherstrasse 74, 01307 Dresden

    Recruiting
  • Universitätsklinikum Erlangen

    Universitaetsstrasse 21-23, 91054 Erlangen

    Recruiting
  • KEM I Evang. Kliniken Essen-Mitte gGmbH

    Henricistrasse 92, 45136 Essen

    In preparation
  • Asklepios Klinik Wandsbek

    Paul-Ehrlich-Strasse 1, 22763 Hamburg

    Recruiting
  • Universitätsklinikum Mannheim Gmbh

    Theodor-Kutzer-Ufer 1-3, 68167 Mannheim

    Recruiting
  • Universitätsklinikum Ulm

    Ulm

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.